Search

Your search keyword '"Masters C"' showing total 1,472 results
Start Over Author "Masters C"
1,472 results on '"Masters C"'

3. Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU): Trial Satisfaction and Attitudes towards Future Clinical Trials

Author

Liu, Haiyan, Li, J., Ziegemeier, E., Adams, S., McDade, E., Clifford, D. B., Cao, Y., Wang, G., Li, Y., Mills, S. L., Santacruz, A. M., Belyew, S., Grill, J. D., Snider, B. J., Mummery, C. J., Surti, G., Hannequin, D., Wallon, D., Berman, S. B., Jimenez-Velazquez, I. Z., Roberson, E. D., van Dyck, C. H., Honig, L. S., Sanchez-Valle, R., Brooks, W. S., Gauthier, S., Galasko, D., Masters, C. L., Brosch, J., Hsiung, G.-Y. R., Jayadev, S., Formaglio, M., Masellis, M., Clarnette, R., Pariente, J., Dubois, B., Pasquier, F., Bateman, R. J., and Llibre-Guerra, Jorge J.

Published
2024
Full Text
View/download PDF

5. Can We Use Blood Biomarkers as Entry Criteria and for Monitoring Drug Treatment Effects in Clinical Trials? A Report from the EU/US CTAD Task Force

Author

Angioni, D., Hansson, O., Bateman, R. J., Rabe, C., Toloue, M., Braunstein, J. B., Agus, S., Sims, J. R., Bittner, T., Carrillo, M. C., Fillit, H., Masters, C. L., Salloway, S., Aisen, P., Weiner, M., Vellas, B., Gauthier, S., Abushakra, Susan, Afshar, Mohammad, Alam, John, Algeciras-Schimnich, Alicia, Andrieu, Sandrine, Ballard, Clive, Baruch, Amos, Batrla, Richard, Baudler, Monika, Bell, Joanne, Bozeat, Sasha, Brooks, Dawn, Brooks, Tricia, Bullain, Szofia, Burmeister, Jan, Cho, Min, Collins, Emily, Cook, Gavin, Cummings, Jeffrey, Dague, Chris, De Santi, Susan, Doody, Rachelle, Dunn, Billy, Egan, Michael, Eriksson, Sven, Esquivel, Rianne, Fagan, Tom, Ferrell, Phyllis, Gallagher, Michela, Grönblad, Anna-Kaija, Hains, Avis, Hampel, Harald, Hefting, Nanco, Hendrix, Suzanne, Ho, Carole, Hu, Helen, Ismail, Zahinoor, Jones, Daryl, Kinney, Gene, Kinnon, Paul, Kurzman, Ricky, Lannfelt, Lars, Lawson, John, LeBastard, Nathalie, Legrand, Valérie, Lewandowski, Nicole, Lim, Carine, Lyketsos, Costantine, Masterman, Donna, Lu, Ming, Mintun, Mark, Molinuevo, José Luis, Monteiro, Cecilia, Navia, Bradford, Odergren, Tomas, Osswald, Gunilla, Penny, Lewis, Pontecorvo, Michael, Porsteinsson, Anton, Raman, Rema, Respondek, Gesine, Reyderman, Larisa, Rogers, Sharon, Rosenberg, Paul, Rosenzweig-Lipson, Sharon, Roskey, Mark, Carrie, Rubel, Saad, Ziad, Schindler, Rachel, Selkoe, Dennis, Shulman, Melanie, Sink, Kaycee, Sipe, Lisa, Skovronsky, Daniel, Somers, Elizabeth, Soto, Maria, Streffer, Johannes, Such, Pedro, Suhy, Joyce, Touchon, Jacques, Vandijck, Manu, White, Anne, Wilson, David, Zago, Wagner, and Zhou, Jin

Published
2023
Full Text
View/download PDF

7. Accuracy of TrUE-Net in comparison to established white matter hyperintensity segmentation methods: An independent validation study.

Author

Strain, JF, Rahmani, M, Dierker, D, Owen, C, Jafri, H, Vlassenko, AG, Womack, K, Fripp, J, Tosun, D, Benzinger, TLS, Weiner, M, Masters, C, Lee, J-M, Morris, JC, Goyal, MS, ADOPIC and ADNI Investigators, Strain, JF, Rahmani, M, Dierker, D, Owen, C, Jafri, H, Vlassenko, AG, Womack, K, Fripp, J, Tosun, D, Benzinger, TLS, Weiner, M, Masters, C, Lee, J-M, Morris, JC, Goyal, MS, and ADOPIC and ADNI Investigators

Abstract

White matter hyperintensities (WMH) are nearly ubiquitous in the aging brain, and their topography and overall burden are associated with cognitive decline. Given their numerosity, accurate methods to automatically segment WMH are needed. Recent developments, including the availability of challenge data sets and improved deep learning algorithms, have led to a new promising deep-learning based automated segmentation model called TrUE-Net, which has yet to undergo rigorous independent validation. Here, we compare TrUE-Net to six established automated WMH segmentation tools, including a semi-manual method. We evaluated the techniques at both global and regional level to compare their ability to detect the established relationship between WMH burden and age. We found that TrUE-Net was highly reliable at identifying WMH regions with low false positive rates, when compared to semi-manual segmentation as the reference standard. TrUE-Net performed similarly or favorably when compared to the other automated techniques. Moreover, TrUE-Net was able to detect relationships between WMH and age to a similar degree as the reference standard semi-manual segmentation at both the global and regional level. These results support the use of TrUE-Net for identifying WMH at the global or regional level, including in large, combined datasets.

Published
2024

11. 12415 Surgical Management of Undescended Gonads for Androgen Insensitivity Syndrome.

Author

Gonzalez Pena, TI, Cook, EN, Masters, C, Roach, M, and Anderson, T

Abstract

To demonstrate a surgical technique for management of undescended testicular tissue for patients with complete androgen insensitivity syndrome. Narrated surgical presentation. Androgen insensitivity syndrome (AIS) is an X-linked genetic disorder characterized by peripheral androgen resistance due to androgen receptor mutations in subjects with 46 XY karyotype. Despite normal testicular development, the testes are often retained in the abdomen or inguinal canal. Gonadectomy is usually recommended because undescended testicular tissue presents increased risk of malignant transformation after puberty. Video footage and operative photos were used with obtained consent from one patient undergoing laparoscopic bilateral gonadectomy. The patient underwent laparoscopic bilateral gonadectomy. N/A. AIS is rare genetic disorder in which androgen receptor mutation leads to female secondary sex characteristics despite testes formation. For complete AIS, gonadectomy is recommended post-puberty to decrease risk of malignant transformation of testicular tissue. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

16. A[Beta] Deposits in Older Non-Demented Individuals with Cognitive Decline Are Indicative of Preclinical Alzheimer's Disease

Author

Villemagne, V. L., Pike, K. E., Darby, D., Maruff, P., Savage, G., Ng, S., Ackermann, U., Cowie, T. F., Currie, J., Chan, S. G., Jones, G., Tochon-Danguy, H., O'Keefe, G., Masters, C. L., and Rowe, C. C.

Abstract

Approximately 30% of healthy persons aged over 75 years show A[beta] deposition at autopsy. It is postulated that this represents preclinical Alzheimer's disease (AD). We evaluated the relationship between A[beta] burden as assessed by PiB PET and cognitive decline in a well-characterized, non-demented, elderly cohort. PiB PET studies and cognitive tests were performed on 34 elderly participants (age 73 [plus or minus] 6) from the longitudinal Melbourne Healthy Aging Study (MHAS). Subjects were classified as being cognitively "stable" or "declining" by an independent behavioural neurologist based on clinical assessment and serial word-list recall scores from the preceding 6-10 years. Decline was calculated from the slope of the word-list recall scores. A[beta] burden was quantified using Standardized Uptake Value normalized to cerebellar cortex. Ten subjects were clinically classified as declining. At the time of the PET scans, three of the declining subjects had mild cognitive impairment, one had AD, and six were declining but remained within the normal range for age on cognitive tests. Declining subjects were much more likely to show cortical PiB binding than stable subjects (70% vs. 17%, respectively). Neocortical A[beta] burden correlated with word-list recall slopes (r = -0.78) and memory function (r = -0.85) in the declining group. No correlations were observed in the stable group. A[beta] burden correlated with incident memory impairment and the rate of memory decline in the non-demented ageing population. These observations suggest that neither memory decline nor A[beta] deposition are part of normal ageing and likely represent preclinical AD. Further longitudinal observations are required to confirm this hypothesis. (Contains 4 tables and 4 figures.)

Published
2008
Full Text
View/download PDF

40. Improved locomotor function and survival of mice with increased levels of mutant superoxide dismutase 1: O03-4

Author

Roberts, B. R., Lim, N. K. H., McAllum, E. J., Donnelly, P. S., Hare, D. J., Doble, P. A., Turner, B. J., Price, K. A., Lim, S. C., Paterson, B. M., Hickey, J. L., Rhoads, T. W., Williams, J. R., Kanninen, K. M., Hung, L. W., Liddell, J. R., Grubman, A., Monty, J. F., Llanos, R. M., Kramer, D. R., Mercer, J. F. B., Bush, A. I., Masters, C. L., Duce, J. A., Li, Q. X., Beckman, J. S., Barnham, K. J., White, A. R., and Crouch, P. J.

Published
2014

44. Plasma amyloid-beta levels in a pre-symptomatic Dutch-type hereditary cerebral amyloid angiopathy pedigree: A cross-sectional and longitudinal investigation

Author

Chatterjee, P., Tegg, M., Pedrini, S., Fagan, A., Xiong, C., Singh, A., Taddei, K., Gardener, S., Masters, C., Schofield, P., Multhaup, G., Benzinger, T., Morris, J., Bateman, R., Greenberg, S., van Buchem, M., Stoops, E., Vanderstichele, H., Teunissen, C., Hankey, G., Wermer, M., Sohrabi, H., Martins, R.N., the Dominantly Inherited Alzheimer Network, Chatterjee, P., Tegg, M., Pedrini, S., Fagan, A., Xiong, C., Singh, A., Taddei, K., Gardener, S., Masters, C., Schofield, P., Multhaup, G., Benzinger, T., Morris, J., Bateman, R., Greenberg, S., van Buchem, M., Stoops, E., Vanderstichele, H., Teunissen, C., Hankey, G., Wermer, M., Sohrabi, H., Martins, R.N., and the Dominantly Inherited Alzheimer Network

Abstract

Plasma amyloid-beta (Aβ) has long been investigated as a blood biomarker candidate for Cerebral Amyloid Angiopathy (CAA), however previous findings have been inconsistent which could be attributed to the use of less sensitive assays. This study investigates plasma Aβ alterations between pre-symptomatic Dutch-type hereditary CAA (D-CAA) mutation-carriers (MC) and non-carriers (NC) using two Aβ measurement platforms. Seventeen pre-symptomatic members of a D-CAA pedigree were assembled and followed up 3–4 years later (NC = 8; MC = 9). Plasma Aβ1-40 and Aβ1-42 were cross-sectionally and longitudinally analysed at baseline (T1) and follow-up (T2) and were found to be lower in MCs compared to NCs, cross-sectionally after adjusting for covariates, at both T1(Aβ1-40: p = 0.001; Aβ1-42: p = 0.0004) and T2 (Aβ1-40: p = 0.001; Aβ1-42: p = 0.016) employing the Single Molecule Array (Simoa) platform, however no significant differences were observed using the xMAP platform. Further, pairwise longitudinal analyses of plasma Aβ1-40 revealed decreased levels in MCs using data from the Simoa platform (p = 0.041) and pairwise longitudinal analyses of plasma Aβ1-42 revealed decreased levels in MCs using data from the xMAP platform (p = 0.041). Findings from the Simoa platform suggest that plasma Aβ may add value to a panel of biomarkers for the diagnosis of pre-symptomatic CAA, however, further validation studies in larger sample sets are required.

Published
2021

45. RP25- Sigmoid methodology allows early prediction of cognitive decline towards Alzheimer's disease across several cognitive domains

Author

Cespedes, M., Gillis, C., Maruff, P., Maserejian, N., Fowler, C., Rainey-Smith, S., Villemagne, V., Rowe, C., Martins, R., Masters, C., Doecke, J., Cespedes, M., Gillis, C., Maruff, P., Maserejian, N., Fowler, C., Rainey-Smith, S., Villemagne, V., Rowe, C., Martins, R., Masters, C., and Doecke, J.

Abstract

Background: Clinical trials in Alzheimer’s disease (AD) depend on clinical endpoints that may lack sensitivity to the cognitive changes that characterize the disease prior to dementia diagnosis. Consequently, trials designed to determine whether new drugs can forestall dementia or prevent cognitive decline prior to onset of AD dementia will require outcomes measures that are sensitive to cognitive changes earlier in the disease. Objectives: The objective of this work was to identify individuals whose cognitive scores progress more rapidly (“accelerators”) from those whose cognition does not reach this same level over the same time period (“non-accelerators”). The specific aim was to assess the MMSE, CDR-SB and seven different cognitive composite scores to examine 1) their ability to cluster accelerators and non- accelerators, 2) which cognitive scores can be used as strong predictors of cognitive change, and 3) the proportion agreement of progression classification within specific subgroups of AD pathology. This process was entirely data driven in that it was performed without using the formal AIBL clinical classification to inform disease stage. Methods: Using longitudinal data from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of ageing, seven cognitive composite scores (the AIBL PACC score (CVLT-II, LMII, DSC & MMSE), attention and processing speed (DSC & total digit span), episodic memory (delayed recall, LMII & RCFT30), executive function (verbal fluency & category switching), language (BNT & verbal fluency [D-KEFS]), recognition (recognition CVLT-II & RCFT), visuospatial function (RCFT copy & clock along) along with MMSE and CDR-SB from 144 months of AIBL were selected from all participants with at least three time points (at baseline: total N=1269; 973 Cognitively Normal (CN), 143 with Mild Cognitive Impairment (MCI), 153 with AD). Using the mathematical properties of a proposed sigmoidal function, “cognitive turning points” are defined to all

Published
2021

47. CLINICAL AND BIOMARKER CHANGES IN DOMINANTLY INHERITED ALZHEIMERʼS DISEASE: P01-04

Author

Schofield, P R, Bateman, R J, Xiong, C, Benzinger, T LS, Fagan, A M, Goate, A, Fox, N C, Marcus, D S, Cairns, N J, Xie, X, Blazey, T M, Holtzman, D M, Santacruz, A, Buckles, V, Oliver, A, Moulder, K, Aisen, P S, Ghetti, B, Klunk, W E, McDade, E, Martins, R N, Masters, C L, Mayeux, R, Ringman, J M, Rossor, M N, Sperling, R A, Salloway, S, and Morris, J C

Published
2013

Catalog

Books, media, physical & digital resources
See catalog results